Trinity Biotech

Trinity Biotech FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Trinity Biotech (TRIB) as of Nov 11, 2026 is 32.51 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 44.84 % — a change of -27.50% (lower).

FCF Conversion

32.51 %

YoY

-27.50%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Trinity Biotech is 2025 32.51 % . FCF Conversion Rate (FCF/EBITDA) of Trinity Biotech was 2024 44.84 % . It decreases by -27.50% lower compared to the previous year.

The Trinity Biotech FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-433.10 USD
Jan 1, 2019
243.02 USD
Jan 1, 2020
-212.23 USD
Jan 1, 2021
519.66 USD
Jan 1, 2022
16.82 USD
Jan 1, 2023
51.46 USD
Jan 1, 2024
44.84 USD
Jan 1, 2025
32.51 USD
The Trinity Biotech FCF Conversion history
YEARFCF ConversionYoY
32.51 %-27.50%
44.84 %-12.86%
51.46 %+205.89%
16.82 %-96.76%
519.66 %-344.86%
-212.23 %-187.33%
243.02 %-156.11%
-433.10 %-4,198.89%
10.57 %+25.00%
8.45 %-117.75%
-47.63 %+0.16%
-47.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

FCF Conversion Rate (FCF/EBITDA) of Trinity Biotech is 32.51 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Trinity Biotech changed from 44.84 % to 32.51 %, representing a -27.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Trinity Biotech

All Key Metrics — Trinity Biotech